Efficacy of Hypoglycemic Agents in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A Systematic Review and Network Meta-Analysis.

Ren Q, Tan Y, Zhang G, Dai Y, Yang L, Wu Y, He H, Chen J

Journal of evidence-based medicine1 Jun 2025Cited by 8 (Europe PMC)

PMID40229658DOI10.1111/jebm.70021PepBankPUB-40229658

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

3 results from studies that gave the peptide. 3 results from people.

01HumanSystematic reviewEfficacy outcome
In reviewed adults with MASLD, liraglutide showed significant body weight benefits; the signed effect coefficient and exact comparison were unstated.
In plain wordsIn reviewed adults with MASLD, liraglutide showed body weight benefits; direction and comparison were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
whereas liraglutide showed significant benefits in body weight, body mass index (BMI), and waist circumference.
3 context sentences(design, population, supporting numbers)
Summary · context
China National Knowledge Infrastructure（CNKI）, WanFang, Weipu, PubMed, Embase, The Cochrane Library, and Web of Science Core Collection were searched for RCTs on the efficacy of hypoglycemic agents in MASLD published up to December 31, 2024.
Summary · context
The network meta-analysis was conducted using Bayesian statistical methods.
Summary · context
Several hypoglycemic agents can improve laboratory and imaging indicators in adult patients with MASLD.
Report a problemFND-4022965801
02HumanSystematic reviewEfficacy outcome
In reviewed adults with MASLD, liraglutide showed significant BMI benefits; the signed effect coefficient and exact comparison were unstated.
In plain wordsIn reviewed adults with MASLD, liraglutide showed BMI benefits; direction and comparison were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedBMI
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
whereas liraglutide showed significant benefits in body weight, body mass index (BMI), and waist circumference.
3 context sentences(design, population, supporting numbers)
Summary · context
China National Knowledge Infrastructure（CNKI）, WanFang, Weipu, PubMed, Embase, The Cochrane Library, and Web of Science Core Collection were searched for RCTs on the efficacy of hypoglycemic agents in MASLD published up to December 31, 2024.
Summary · context
The network meta-analysis was conducted using Bayesian statistical methods.
Summary · context
Several hypoglycemic agents can improve laboratory and imaging indicators in adult patients with MASLD.
Report a problemFND-4022965802
03HumanSystematic reviewEfficacy outcome
In reviewed adults with MASLD, liraglutide showed significant waist circumference benefits; the signed effect coefficient and exact comparison were unstated.
In plain wordsIn reviewed adults with MASLD, liraglutide showed waist circumference benefits; direction and comparison were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedWaist circumference
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
whereas liraglutide showed significant benefits in body weight, body mass index (BMI), and waist circumference.
3 context sentences(design, population, supporting numbers)
Summary · context
China National Knowledge Infrastructure（CNKI）, WanFang, Weipu, PubMed, Embase, The Cochrane Library, and Web of Science Core Collection were searched for RCTs on the efficacy of hypoglycemic agents in MASLD published up to December 31, 2024.
Summary · context
The network meta-analysis was conducted using Bayesian statistical methods.
Summary · context
Several hypoglycemic agents can improve laboratory and imaging indicators in adult patients with MASLD.
Report a problemFND-4022965803

Studies that did not test the peptide alone8

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed adults with MASLD, inflammatory markers changed minimally across pooled hypoglycemic agents including liraglutide; the reference and statistical test were unstated.
In plain wordsIn reviewed adults with MASLD, pooled diabetes drugs including liraglutide showed minimal inflammatory markers changes; comparison and statistical test were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedInflammatory markers
Study
n: not reported in source
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
Secondary outcomes such as inflammatory markers and fibrosis showed minimal changes.
4 context sentences(design, population, supporting numbers)
Summary · context
China National Knowledge Infrastructure（CNKI）, WanFang, Weipu, PubMed, Embase, The Cochrane Library, and Web of Science Core Collection were searched for RCTs on the efficacy of hypoglycemic agents in MASLD published up to December 31, 2024.
Summary · context
The network meta-analysis was conducted using Bayesian statistical methods.
Summary · context
A total of 26 hypoglycemic agents for treating MASLD in 37 studies with 2406 participants were included.
Summary · context
Several hypoglycemic agents can improve laboratory and imaging indicators in adult patients with MASLD.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4022965810
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed adults with MASLD, fibrosis changed minimally across pooled hypoglycemic agents including liraglutide; the reference and statistical test were unstated.
In plain wordsIn reviewed adults with MASLD, pooled diabetes drugs including liraglutide showed minimal fibrosis changes; comparison and statistical test were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedFibrosis
Study
n: not reported in source
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Secondary outcomes such as inflammatory markers and fibrosis showed minimal changes.
4 context sentences(design, population, supporting numbers)
Summary · context
China National Knowledge Infrastructure（CNKI）, WanFang, Weipu, PubMed, Embase, The Cochrane Library, and Web of Science Core Collection were searched for RCTs on the efficacy of hypoglycemic agents in MASLD published up to December 31, 2024.
Summary · context
The network meta-analysis was conducted using Bayesian statistical methods.
Summary · context
A total of 26 hypoglycemic agents for treating MASLD in 37 studies with 2406 participants were included.
Summary · context
Several hypoglycemic agents can improve laboratory and imaging indicators in adult patients with MASLD.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4022965811
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed adults with MASLD, pooled GLP-1RA evidence including liraglutide showed ALT improvements; the signed coefficient and exact comparison were unstated.
In plain wordsIn reviewed adults with MASLD, pooled GLP-1 drugs showed ALT benefits; direction and comparison were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedALT
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide) improved liver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyltransferase [GGT]), glucose metabolism (fasting plasma glucose [FPG], and homeostasis model assessment of insulin resistance […
3 context sentences(design, population, supporting numbers)
Summary · context
China National Knowledge Infrastructure（CNKI）, WanFang, Weipu, PubMed, Embase, The Cochrane Library, and Web of Science Core Collection were searched for RCTs on the efficacy of hypoglycemic agents in MASLD published up to December 31, 2024.
Summary · context
The network meta-analysis was conducted using Bayesian statistical methods.
Summary · context
Several hypoglycemic agents can improve laboratory and imaging indicators in adult patients with MASLD.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4022965804
07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed adults with MASLD, pooled GLP-1RA evidence including liraglutide showed AST improvements; the signed coefficient and exact comparison were unstated.
In plain wordsIn reviewed adults with MASLD, pooled GLP-1 drugs showed AST benefits; direction and comparison were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedAST
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide) improved liver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyltransferase [GGT]), glucose metabolism (fasting plasma glucose [FPG], and homeostasis model assessment of insulin resistance […
3 context sentences(design, population, supporting numbers)
Summary · context
China National Knowledge Infrastructure（CNKI）, WanFang, Weipu, PubMed, Embase, The Cochrane Library, and Web of Science Core Collection were searched for RCTs on the efficacy of hypoglycemic agents in MASLD published up to December 31, 2024.
Summary · context
The network meta-analysis was conducted using Bayesian statistical methods.
Summary · context
Several hypoglycemic agents can improve laboratory and imaging indicators in adult patients with MASLD.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4022965805
08HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed adults with MASLD, pooled GLP-1RA evidence including liraglutide showed GGT improvements; the signed coefficient and exact comparison were unstated.
In plain wordsIn reviewed adults with MASLD, pooled GLP-1 drugs showed GGT benefits; direction and comparison were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedGGT
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide) improved liver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyltransferase [GGT]), glucose metabolism (fasting plasma glucose [FPG], and homeostasis model assessment of insulin resistance […
3 context sentences(design, population, supporting numbers)
Summary · context
China National Knowledge Infrastructure（CNKI）, WanFang, Weipu, PubMed, Embase, The Cochrane Library, and Web of Science Core Collection were searched for RCTs on the efficacy of hypoglycemic agents in MASLD published up to December 31, 2024.
Summary · context
The network meta-analysis was conducted using Bayesian statistical methods.
Summary · context
Several hypoglycemic agents can improve laboratory and imaging indicators in adult patients with MASLD.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4022965806
09HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed adults with MASLD, pooled GLP-1RA evidence including liraglutide showed fasting plasma glucose improvements; the signed coefficient and exact comparison were unstated.
In plain wordsIn reviewed adults with MASLD, pooled GLP-1 drugs showed fasting glucose benefits; direction and comparison were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedFasting plasma glucose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide) improved liver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyltransferase [GGT]), glucose metabolism (fasting plasma glucose [FPG], and homeostasis model assessment of insulin resistance […
3 context sentences(design, population, supporting numbers)
Summary · context
China National Knowledge Infrastructure（CNKI）, WanFang, Weipu, PubMed, Embase, The Cochrane Library, and Web of Science Core Collection were searched for RCTs on the efficacy of hypoglycemic agents in MASLD published up to December 31, 2024.
Summary · context
The network meta-analysis was conducted using Bayesian statistical methods.
Summary · context
Several hypoglycemic agents can improve laboratory and imaging indicators in adult patients with MASLD.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4022965807
10HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed adults with MASLD, pooled GLP-1RA evidence including liraglutide showed HOMA-IR improvements; the signed coefficient and exact comparison were unstated.
In plain wordsIn reviewed adults with MASLD, pooled GLP-1 drugs showed insulin-resistance marker benefits; direction and comparison were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedHOMA-IR
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide) improved liver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyltransferase [GGT]), glucose metabolism (fasting plasma glucose [FPG], and homeostasis model assessment of insulin resistance […
3 context sentences(design, population, supporting numbers)
Summary · context
China National Knowledge Infrastructure（CNKI）, WanFang, Weipu, PubMed, Embase, The Cochrane Library, and Web of Science Core Collection were searched for RCTs on the efficacy of hypoglycemic agents in MASLD published up to December 31, 2024.
Summary · context
The network meta-analysis was conducted using Bayesian statistical methods.
Summary · context
Several hypoglycemic agents can improve laboratory and imaging indicators in adult patients with MASLD.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4022965808
11HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed adults with MASLD, pooled GLP-1RA evidence including liraglutide showed lipid profiles improvements; the signed coefficient and exact comparison were unstated.
In plain wordsIn reviewed adults with MASLD, pooled GLP-1 drugs showed blood lipids benefits; direction and comparison were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedLipid profiles
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide) improved liver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyltransferase [GGT]), glucose metabolism (fasting plasma glucose [FPG], and homeostasis model assessment of insulin resistance […
3 context sentences(design, population, supporting numbers)
Summary · context
China National Knowledge Infrastructure（CNKI）, WanFang, Weipu, PubMed, Embase, The Cochrane Library, and Web of Science Core Collection were searched for RCTs on the efficacy of hypoglycemic agents in MASLD published up to December 31, 2024.
Summary · context
The network meta-analysis was conducted using Bayesian statistical methods.
Summary · context
Several hypoglycemic agents can improve laboratory and imaging indicators in adult patients with MASLD.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4022965809

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.